|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
|
(Address of principal executive offices)
|
|
|
(Zip Code)
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
|
|
|
The
|
|
|
|
|
The
|
|
|
|
|
The
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
||
|
☒
|
Smaller reporting company
|
|
||
Emerging growth company
|
|
|
|
Page
No. |
PART I. FINANCIAL INFORMATION
|
||
Item 1.
|
1
|
|
1
|
||
2
|
||
3
|
||
4
|
||
5
|
||
Item 2.
|
19 | |
Item 3.
|
24 |
|
Item 4.
|
24 |
|
PART II. OTHER INFORMATION
|
||
Item 1.
|
25 |
|
Item 1A.
|
25 |
|
Item 2.
|
25 |
|
Item 3.
|
26 |
|
Item 4.
|
26 |
|
Item 5.
|
26 |
|
Item 6.
|
26 |
|
27 |
|
June 30,
|
December 31,
|
||||||
|
2023
|
2022
|
||||||
Unaudited
|
||||||||
Assets:
|
||||||||
Current assets:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Prepaid expenses
|
|
|
||||||
Total current assets
|
|
|
||||||
|
||||||||
Cash and investments held in Trust Account
|
|
|
||||||
Total Assets
|
$
|
|
$
|
|
||||
|
||||||||
Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit:
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
|
$
|
|
||||
Accrued expenses
|
|
|
||||||
Accrued expenses - related party
|
|
|
||||||
Total current liabilities
|
|
|
||||||
|
||||||||
Deferred legal fees
|
|
|
||||||
Deferred underwriting commissions
|
|
|
||||||
|
|
|
||||||
Derivative warrant liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
|
||||||||
Commitments and Contingencies
|
||||||||
Class A ordinary shares;
|
|
|
||||||
|
||||||||
Shareholders’ Deficit:
|
||||||||
Preference shares, $
|
|
|
||||||
Class A ordinary shares, $
|
|
|
||||||
Class B ordinary shares, $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Total shareholders’ deficit
|
(
|
)
|
(
|
)
|
||||
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
|
$
|
|
$
|
|
|
For the Three Months
Ended June 30, |
For the Six Months
Ended June 30,
|
||||||||||||||
|
2023
|
2022
|
2023 |
2022 |
||||||||||||
General and administrative expenses
|
$
|
|
$
|
|
$ | $ | ||||||||||
Loss from operations
|
(
|
)
|
(
|
)
|
( |
) | ( |
) | ||||||||
|
||||||||||||||||
Other income:
|
||||||||||||||||
Change in fair value of derivative liabilities
|
|
|
( |
) | ||||||||||||
Reduction in deferred underwriter commissions |
||||||||||||||||
Interest income – bank
|
|
|
||||||||||||||
Interest expense
|
|
(
|
)
|
( |
) | |||||||||||
Investment income earned on cash and investments held in Trust Account
|
|
|
||||||||||||||
Total other income, net
|
|
|
||||||||||||||
|
||||||||||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
$ | ( |
) | $ | |||||||
|
||||||||||||||||
Weighted average Class A ordinary shares, basic and diluted
|
|
|
||||||||||||||
Basic and diluted net (loss) income per ordinary share, Class A
|
$
|
(
|
)
|
$
|
|
$ | ( |
) | $ | |||||||
|
||||||||||||||||
Weighted average Class B ordinary shares, basic and diluted
|
|
|
||||||||||||||
Basic and diluted net (loss) income per ordinary share, Class B
|
$
|
(
|
)
|
$
|
|
$ | ( |
) | $ |
|
Ordinary Shares
|
Additional
|
Total
|
|||||||||||||||||||||||||
|
Class A
|
Class B
|
Paid-in
|
Accumulated
|
Shareholders’
|
|||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Deficit
|
|||||||||||||||||||||
Balance - December 31, 2022
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||
Remeasurement adjustment of Class A ordinary shares subject to possible redemption
|
—
|
|
—
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
Net loss
|
—
|
|
—
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||
Balance – March 31, 2023
|
|
|
|
|
|
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||
Reduction in deferred underwriting commissions
|
— | — | ||||||||||||||||||||||||||
Remeasurement adjustment of Class A ordinary shares subject to possible redemption
|
— | — | ||||||||||||||||||||||||||
Net loss |
— | — | ( |
) | ( |
) | ||||||||||||||||||||||
Balance – June 30, 2023 | $ | $ | $ | $ | ( |
) | $ | ( |
) |
|
Ordinary Shares
|
Additional
|
Total
|
|||||||||||||||||||||||||
|
Class A
|
Class B
|
Paid-in
|
Accumulated
|
Shareholders’
|
|||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Deficit
|
|||||||||||||||||||||
Balance – December 31, 2021
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||||||||||
Net income
|
—
|
|
—
|
|
|
|
|
|||||||||||||||||||||
Balance – March 31, 2022 (unaudited)
|
|
|
|
|
|
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||
Increase in redemption value of Class A ordinary shares subject to possible redemption
|
— | — | ( |
) | ( |
) | ||||||||||||||||||||||
Net income |
— | — | ||||||||||||||||||||||||||
Balance – June 30, 2022 (unaudited)
|
$ | $ | $ | $ | ( |
) | $ | ( |
) |
|
For the Six Months Ended
June 30,
|
|||||||
|
2023
|
2022
|
||||||
Cash Flows from Operating Activities:
|
||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
|||
Adjustments to reconcile net (loss) income to net cash used in operating activities:
|
||||||||
Change in fair value of derivative liabilities
|
|
(
|
)
|
|||||
Interest expense
|
|
|
||||||
Investment income earned on cash and investments held in Trust Account
|
(
|
)
|
(
|
)
|
||||
Reduction in deferred underwriting commissions |
( |
) | ||||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses
|
|
|
||||||
Accounts payable
|
(
|
)
|
|
|||||
Accrued expenses - related party
|
|
|
||||||
Accrued expenses
|
|
|
||||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
||||
|
||||||||
Cash Flows from Investing Activities:
|
||||||||
Cash withdrawn from Trust Account for working capital purposes |
||||||||
Cash withdrawn from Trust Account in connection with redemption
|
|
|
||||||
Net cash provided by investing activities
|
|
|
||||||
|
||||||||
Cash Flows from Financing Activities:
|
||||||||
Proceeds from convertible promissory note - related party
|
|
|
||||||
Redemption of common stock
|
(
|
)
|
|
|||||
Net cash (used in) provided by financing activities
|
(
|
)
|
|
|||||
|
||||||||
Net increase in cash
|
|
|
||||||
Cash - beginning of the period
|
|
|
||||||
Cash - end of the period
|
$
|
|
$
|
|
||||
|
||||||||
Supplemental disclosure of noncash investing and financing activities:
|
||||||||
Increase in value of Class A common stock subject to possible redemption
|
$
|
|
$
|
|
||||
Reduction in deferred underwriting fee payable
|
$ | $ |
|
•
|
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
|
•
|
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices
for identical or similar instruments in markets that are not active; and
|
•
|
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in
which one or more significant inputs or significant value drivers are unobservable.
|
|
For the Three Months Ended June 30,
|
For the Six Months Ended June 30, |
||||||||||||||||||||||||||||||
|
2023
|
2022
|
2023 |
2022
|
||||||||||||||||||||||||||||
|
Class A
|
Class B
|
Class A
|
Class B
|
Class A |
Class B |
Class A |
Class B |
||||||||||||||||||||||||
Basic and diluted net (loss) income per common share:
|
||||||||||||||||||||||||||||||||
Numerator:
|
||||||||||||||||||||||||||||||||
Allocation of net (loss) income
|
$ | ( |
) |
$
|
(
|
)
|
$ | $ | $ | ( |
) | $ | ( |
) | $ | $ | ||||||||||||||||
Denominator:
|
||||||||||||||||||||||||||||||||
Basic and diluted weighted average common shares outstanding
|
|
|
|
|||||||||||||||||||||||||||||
Basic and diluted net (loss) income per common share
|
$
|
(
|
)
|
$
|
(
|
)
|
$ | $ | $ | ( |
) | $ | ( |
) | $ | $ |
•
|
by written consent of H2B2 and the Company;
|
•
|
by H2B2 or the Company if any governmental authority has enacted, issued, promulgated, enforced or entered any law or governmental order which has become final and non-appealable and has the effect of
making consummation of the transactions contemplated by the Merger Agreement and the Ancillary Agreements (as defined in the Merger Agreement) illegal or otherwise enjoining, preventing or prohibiting the consummation of the
transactions contemplated by the Merger Agreement and the Ancillary Agreements (provided that such party did not cause such enactment);
|
•
|
by H2B2 or the Company if the consummation of the Transactions has not occurred on or prior to June 30, 2024, subject to certain automatic extensions, for reasons not primarily due to the terminating
party’s breach or violation of the terms of the Merger Agreement;
|
•
|
by H2B2 or the Company if such party disagrees with the final determination of the Closing Date Purchase Price (as defined in the Merger Agreement) by the valuation firm as further described in the
Merger Agreement;
|
•
|
by H2B2 if there has been a modification in recommendation of the Company’s board of directors with respect to any of the Proposals (as defined in the Merger Agreement);
|
•
|
by H2B2 if the Company has not obtained shareholder approval for the Transactions by reason of the failure to obtain the required vote at a meeting of the Company’s shareholders;
|
•
|
by H2B2 if (i) prior to completion of a Capital Raise Transaction (as defined in the Merger Agreement), a Capital Raise Investor (as defined in the Merger Agreement) or group of Capital Raise
Investors, with legal, valid and binding commitments to fund in such Capital Raise Transaction represent in the aggregate at least the Minimum Investment Amount (as defined in the Merger Agreement) object to the Merger and the other
transactions contemplated by the Merger Agreement by delivering a written notice to the board of directors of H2B2 by no later than
|
•
|
by H2B2 in the event of an uncured breach of any representation, warranty, covenant or agreement on the part of the Company, except if the breach is curable by the Company through the exercise of its
reasonable best efforts, then, for a period of up to
(30) days after receipt by the Company of notice from H2B2
of such breach, but only as long as the Company continues to exercise such reasonable best efforts to cure such breach, such termination will not be effective, and such termination will be effective only if such breach is not cured
within the -day period; |
•
|
by the Company in the event of an uncured breach of any representation, warranty, covenant or agreement on the part of H2B2, except if the breach is curable by H2B2 through the exercise of its
reasonable best efforts, then, for a period of up to
(30) days after receipt by H2B2 of notice from the Company
of such breach, but only as long as H2B2 continues to exercise such reasonable best efforts to cure such breach, such termination will not be effective, and such termination will be effective only if such breach is not cured within
the -day period; |
•
|
by the Company if the H2B2 Stockholder Approval has not been obtained; and
|
•
|
by the Company if an H2B2 stockholder exercises any right or takes any action or fails to take any action required to satisfy the conditions or any closing deliverables required to be delivered under
the Merger Agreement that prevents consummation of the Merger and the other transactions contemplated by the Merger Agreement and the Ancillary Agreements.
|
Class A ordinary shares subject to possible redemption at December 31, 2021
|
$
|
|
||
Increase in redemption value of Class A ordinary shares subject to possible redeem
|
|
|||
Class A ordinary shares subject to possible redemption at December 31, 2022
|
|
|||
Redemptions of Class A ordinary shares
|
(
|
)
|
||
Increase in redemption value of Class A ordinary shares subject to possible redeem
|
|
|||
Class A ordinary shares subject to possible redemption at June 30, 2023
|
$
|
|
•
|
in whole and not in part;
|
•
|
at a price of $
|
•
|
upon not less than
|
•
|
if, and only if, the last reported sale price (the “closing price”) of Class A ordinary shares equals or exceeds $
|
•
|
in whole and not in part;
|
•
|
at $
|
•
|
if, and only if, the closing price of Class A ordinary shares equals or exceeds $
|
•
|
if the closing price of the Class A ordinary shares for any
|
Description
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Assets:
|
||||||||||||
Cash held in Trust Account
|
$
|
|
$
|
—
|
$
|
—
|
||||||
Liabilities:
|
||||||||||||
Derivative liabilities - Public Warrants
|
$
|
|
$
|
—
|
$
|
—
|
||||||
Derivative liabilities - Private Warrants
|
$
|
—
|
$
|
—
|
$
|
|
Description
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
Assets:
|
||||||||||||
Investments held in Trust Account - Money Market Funds
|
$
|
|
$
|
—
|
$
|
—
|
||||||
Liabilities:
|
||||||||||||
Derivative liabilities - Public Warrants
|
$
|
|
$
|
—
|
$
|
—
|
||||||
Derivative liabilities - Private Warrants
|
$
|
—
|
$
|
—
|
$
|
|
Private Warrants
|
As of
December 31, 2022
|
As of
June 30,
2023
|
||||||
Stock price
|
$
|
|
$
|
|
||||
Volatility
|
|
%
|
|
%
|
||||
Expected life of the options to convert
|
|
|
||||||
Risk-free rate
|
|
%
|
|
%
|
||||
Dividend yield
|
|
|
|
December 31,
2022
|
June 30,
2023
|
||||||
Strike price of debt conversion
|
$
|
|
$
|
|
||||
Volatility
|
|
%
|
|
%
|
||||
Expected life of the options to convert
|
|
|
||||||
Risk-free rate
|
|
%
|
|
%
|
||||
Dividend yield
|
|
|
|
Private
Warrants
|
|||
Derivative warrant liabilities at December 31, 2022
|
$
|
|
||
Change in fair value of derivative warrant liabilities
|
|
|||
Derivative warrant liabilities at March 31, 2023
|
|
|||
Change in fair value of derivative warrant liabilities
|
(
|
)
|
||
Derivative warrant liabilities at June 30, 2023
|
$
|
|
|
Private
Warrants
|
|||
Derivative warrant liabilities at December 31, 2021
|
$
|
|
||
Change in fair value of derivative warrant liabilities
|
(
|
)
|
||
Derivative warrant liabilities at March 31, 2022
|
|
|||
Change in fair value of derivative warrant liabilities
|
(
|
)
|
||
Derivative warrant liabilities at June 30, 2022
|
$
|
|
Balance at December 31, 2021
|
$
|
|
||
Initial fair value of the Working Capital Loan Option
|
|
|||
Change in fair value
|
(
|
)
|
||
Balance at December 31, 2022 and June 30, 2023
|
$
|
|
• |
by written consent of H2B2 and the Company;
|
• |
by H2B2 or the Company if any governmental authority has enacted, issued, promulgated, enforced or entered any law or governmental order which has become final and non-appealable and has the effect of making consummation of the
transactions contemplated by the Merger Agreement and the Ancillary Agreements (as defined in the Merger Agreement) illegal or otherwise enjoining, preventing or prohibiting the consummation of the transactions contemplated by the Merger
Agreement and the Ancillary Agreements (provided that such party did not cause such enactment);
|
• |
by H2B2 or the Company if the consummation of the Transactions has not occurred on or prior to June 30, 2024, subject to certain automatic extensions, for reasons not primarily due to the terminating party’s breach or violation of the
terms of the Merger Agreement;
|
• |
by H2B2 or the Company if such party disagrees with the final determination of the Closing Date Purchase Price (as defined in the Merger Agreement) by the valuation firm as further described in the Merger Agreement;
|
• |
by H2B2 if there has been a modification in recommendation of the Company’s board of directors with respect to any of the Proposals (as defined in the Merger Agreement);
|
• |
by H2B2 if the Company has not obtained shareholder approval for the Transactions by reason of the failure to obtain the required vote at a meeting of the Company’s shareholders;
|
• |
by H2B2 if (i) prior to completion of a Capital Raise Transaction (as defined in the Merger Agreement), a Capital Raise Investor (as defined in the Merger Agreement) or group of Capital Raise Investors, with legal, valid and binding
commitments to fund in such Capital Raise Transaction represent in the aggregate at least the Minimum Investment Amount (as defined in the Merger Agreement) object to the Merger and the other transactions contemplated by the Merger
Agreement by delivering a written notice to the board of directors of H2B2 by no later than fifteen days following execution of definitive agreements relating to the Capital Raise Transaction after which time no Capital Raise Investor will
be entitled to object to the Merger and the other transactions contemplated by the Merger Agreement; provided that, upon receipt of the written notice described above, H2B2 will be required to terminate the Merger Agreement on the tenth
business day following receipt of the written notice;
|
• |
by H2B2 in the event of an uncured breach of any representation, warranty, covenant or agreement on the part of the Company, except if the breach is curable by the Company through the exercise of its reasonable best efforts, then, for a
period of up to thirty (30) days after receipt by the Company of notice from H2B2 of such breach, but only as long as the Company continues to exercise such reasonable best efforts to cure such breach, such termination will not be
effective, and such termination will be effective only if such breach is not cured within the thirty-day period;
|
• |
by the Company in the event of an uncured breach of any representation, warranty, covenant or agreement on the part of H2B2, except if the breach is curable by H2B2 through the exercise of its reasonable best efforts, then, for a period
of up to thirty (30) days after receipt by H2B2 of notice from the Company of such breach, but only as long as H2B2 continues to exercise such reasonable best efforts to cure such breach, such termination will not be effective, and such
termination will be effective only if such breach is not cured within the thirty-day period;
|
• |
by the Company if the H2B2 Stockholder Approval has not been obtained; and
|
• |
by the Company if an H2B2 stockholder exercises any right or takes any action or fails to take any action required to satisfy the conditions or any closing deliverables required to be delivered under the Merger Agreement that prevents
consummation of the Merger and the other transactions contemplated by the Merger Agreement and the Ancillary Agreements.
|
Item 1. |
Legal Proceedings
|
Item 1A. |
Risk Factors.
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds from Registered Offerings
|
Item 3. |
Defaults Upon Senior Securities
|
Item 4. |
Mine Safety Disclosures
|
Item 5. |
Other Information
|
Item 6. |
Exhibits.
|
Exhibit
Number
|
Description
|
|
Agreement and Plan of Merger, dated as of May 9, 2023, by and among RMG Acquisition Corp. III and H2B2 Electrolysis Technologies, Inc. (incorporated by reference to Exhibit 2.1 to RMG Acquisition Corp. III’s
Current Report on Form 8-K (File No. 001-40013) filed with the SEC on May 12, 2023).
|
||
Second Amended and Restated Memorandum and Articles of Association of RMG Acquisition Corp. III (incorporated by reference to Exhibit 3.1 to RMG Acquisition Corp. III’s Current Report on Form 8-K (File No.
001-40013) filed with the SEC on January 11, 2023).
|
||
Sponsor Support Agreement, dated as of May 9, 2023, by and among RMG Sponsor III LLC, RMG Acquisition Corp. III and H2B2 Electrolysis Technologies, Inc. (incorporated by reference to Exhibit 10.1 to RMG
Acquisition Corp. III’s Current Report on Form 8-K (File No. 001-40013) filed with the SEC on May 12, 2023).
|
||
Company Stockholder Support Agreement, dated as of May 9, 2023, by and among RMG Acquisition Corp. III, H2B2 Electrolysis Technologies, Inc., and the Persons set forth on Schedule I thereto (incorporated by
reference to Exhibit 10.2 to RMG Acquisition Corp. III’s Current Report on Form 8-K (File No. 001-40013) filed with the SEC on May 12, 2023).
|
||
Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
* |
These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
|
RMG ACQUISITION CORP. III
|
||
By:
|
/s/ Robert S. Mancini
|
|
Name:
|
Robert S. Mancini
|
|
Title:
|
Chief Executive Officer
|